Moxiflox GPO

Moxiflox GPO

moxifloxacin

Manufacturer:

GPO

Distributor:

GPO
Concise Prescribing Info
Contents
Moxifloxacin HCl
Indications/Uses
Adults ≥18 yr w/ infections caused by susceptible strains of acute bacterial exacerbation of chronic bronchitis, acute bacterial sinusitis, community-acquired pneumonia, complicated intra-abdominal infections, complicated & uncomplicated skin & skin structure infections.
Dosage/Direction for Use
Acute bacterial exacerbation of chronic bronchitis 400 mg once daily for 5 days. Acute bacterial sinusitis 400 mg once daily for 10 days. Community-acquired pneumonia 400 mg once daily for 7-14 days. Complicated intra-abdominal infections 400 mg once daily for 5-14 days. Complicated skin & skin structure infections 400 mg once daily for 7-21 days. Uncomplicated skin & skin structure infections 400 mg once daily for 7 days.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to moxifloxacin, fluoroquinolones or quinolones. Tendinitis or tendon rupture associated w/ quinolones.
Special Precautions
Contraindicated in patients w/ history of hypersensitivity. Discontinue treatment at the 1st signs of rash, pain, myalgia or tenodynia. May be harmful to the liver & kidney. Patients w/ known or suspected CNS disorders that predispose to seizure (eg, severe cerebral arteriosclerosis, epilepsy); w/ causative risks of QT prolongation (eg, elderly, CV disease especially arrhythmia, HTN, hypokalemia). Avoid concomitant use w/ drugs known to cause QT prolongation [eg, antiarrhythmics class IA (eg, quinidine, procainamide), class III (eg, amiodarone, sotalol), cisapride, erythromycin, antipsychotics & TCAs]; patients w/ ongoing proarrhythmic conditions eg, significant bradycardia or acute myocardial ischemia. May cause phototoxic reactions or severe hypersensitivity eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme. May alter blood glucose; DM patients. Monitor blood glucose carefully. Peripheral neuropathy. C.difficile-associated diarrhea. Concomitant use w/ warfarin. Increased risk of tendonitis & tendon rupture in elderly patients aged >60 yr, those taking corticosteroids & those w/ kidney, heart or lung transplants. Avoid in patients w/ known history of myasthenia gravis. Prolonged therapy may lead to superinfection. Mild, moderate or severe hepatic insufficiency (Child-Pugh class A, B or C). Pregnancy & lactation. Childn <18 yr. Elderly especially those on corticosteroids.
Adverse Reactions
Headache, dizziness, insomnia; increased Cl & ionized Ca; decreased glucose; nausea, diarrhea, decreased amylase, constipation, vomiting, abdominal pain; decreased serum levels of basophils, eosinophils Hb, PT, RBC & neutrophils, increased serum levels of MCH, neutrophils, PT & WBC; increased/decreased bilirubin; increased albumin; decreased PO2.
Drug Interactions
Decreased GI absorption w/ Al- or Mg-containing antacids, didanosine, Fe & Zn salts, & sucralfate. Slightly reduced Cmax & prolonged time to max plasma conc w/ Ca. Cimetidine may interfere w/ the elimination of fluoroquinolones. Increased risk of tendon rupture w/ corticosteroids (eg, prednisone). Risks of CNS stimulation & convulsive seizures may increase w/ NSAIDs & tramadol. Plasma conc may be reduced w/ rifampin. May increase risk of photosensitization w/ tretinoin. May increase risk of life-threatening cardiac arrhythmias including Torsades de Pointes w/ antiarrhythmics (eg, amiodarone, bretylium, disopyramide, procainamide, quinidine, sotalol), & antipsychotics (eg, iloperidone, paliperidone, phenothiazines, ziprasidone), bepridil, macrolide-related antibiotics (eg, erythromycin), cisapride & TCAs (eg, amitriptyline). Decrease clearance of warfarin. Decreased AUC & Cmax w/ antidiabetics (eg, glyburide). Decrease mean Cmax of atenolol. May decrease effectiveness of live vaccines.
MIMS Class
ATC Classification
J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Presentation/Packing
Form
Moxiflox GPO FC tab 400 mg
Packing/Price
1 × 5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in